Ritucad (rituximab biosimilar) / Cadila - LARVOL DELTA

Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia (MedPageToday) - '"Long-term follow-up showed that ibrutinib plus rituximab had ongoing superiority across clinical outcomes compared to rituximab alone in patients with WM [Waldenstrom's macroglobulinemia] regardless of prior treatment status or MYD88/CXCR4 genotype, confirming its role as a standard of care for WM,' wrote JCO associate editor Suzanne Lentzsch, MD, PhD...commenting on the relevance of the study."

Media quote

Cadila Pharmaceuticals Launches Biosimilar Rituximab Drug Ritucad (Biosimilar Development) - "Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of biosimilar Rituximab for Indian market. Biosimilar Rituximab is used for treatment of blood cancer and rheumatoid arthritis, and will be launched under the brand name Ritucad."

Biosimilar launch • Hematological Malignancies • Oncology • Rheumatoid Arthritis